利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

371 条记录 (耗时 0.029 秒)

    PHARMACEUTICAL COMPOSITIONS CONTAINING BENFOTIAMINE AND ONE OR ONE MORE PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF PAIN CONDITIONS OF NEUROPATHIC ORIGIN
    32.
    发明申请
    PHARMACEUTICAL COMPOSITIONS CONTAINING BENFOTIAMINE AND ONE OR ONE MORE PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF PAIN CONDITIONS OF NEUROPATHIC ORIGIN 审中-公开
    含有BENFOTIAMINE的药物组合物和一种或多种用于治疗神经病原体疼痛症状的药物活性剂

    公开(公告)号：WO2009046801A1

    公开(公告)日：2009-04-16

    申请号：PCT/EP2008/007364

    申请日：2008-09-09

    申请人： MERCK PATENT GMBH ,  BONKE, Dieter ,  MEDINA-SANTILLÁ, Roberto ,  REYES-GARCIA, Gerardo

    发明人： BONKE, Dieter ,  MEDINA-SANTILLÁ, Roberto ,  REYES-GARCIA, Gerardo

    IPC分类号： A61K45/06 ,  A61P29/00

    CPC分类号： A61K45/06 ,  A61K31/51 ,  A61K2300/00

    摘要： The present invention relates to pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents selected from the group consisting of analgesic acting substances, especially pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents selected from the group consisting of gabapentin, pregabalin, XP13512, carbamacepin, amitryptilin, ketorolac, diclofenac, ibuprofen, flurpirtin, paracetamol and dexamethasone, the process for their preparation and their use for the treatment and prevention of conditions and diseases selected from the group consisting of pain conditions of neuropathic origin.

    摘要翻译： 本发明涉及含有苯非胺和一种或多种药物活性剂的药物组合物，所述药物活性剂选自镇痛作用物质，特别是含有苯非胺的药物组合物和一种或多种选自加巴喷丁，普瑞巴林，XP13512， 氨甲蝶呤，阿米替林，酮咯酸，双氯芬酸，布洛芬，氟妥乃啶，对乙酰氨基酚和地塞米松，其制备方法及其用于治疗和预防选自神经源性疼痛病症的病症和疾病的用途。

    BODY FLUID EXPANDERS COMPRISING N-SUBSTITUTED AMINOSULFONIC ACID BUFFERS
    34.
    发明申请
    BODY FLUID EXPANDERS COMPRISING N-SUBSTITUTED AMINOSULFONIC ACID BUFFERS 审中-公开
    包含N-取代氨基酸残基的身体液体扩张剂

    公开(公告)号：WO2009004331A1

    公开(公告)日：2009-01-08

    申请号：PCT/GB2008/002268

    申请日：2008-07-03

    申请人： AQIX LTD ,  REES, Douglas

    发明人： REES, Douglas

    IPC分类号： A01N1/02 ,  A61K47/18

    CPC分类号： A61K47/183 ,  A61K9/0026 ,  A61K31/047 ,  A61K31/14 ,  A61K31/165 ,  A61K31/198 ,  A61K31/205 ,  A61K31/51 ,  A61K31/7004 ,  A61K33/14 ,  A61K38/28 ,  A61K47/02

    摘要： A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The non-phosphate buffer may be a physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pKa value in aqueous solution of from 7.1 to 7.5 at 2O0C, and most preferably N-tris(hydroxymethyl) methyl-2-aminoethanesulfonic acid (TES), 3-(N-morpholino) propanesulfonic acid (MOPS), N,N-bis (2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) and combinations thereof. Preferred components include from 100 to 150 (preferably about 135) mmoles/L sodium ions, from 2.5 to 6.2 (preferably about 5) mmoles/L potassium ions, from 0.1 to 2.5 (preferably about 1.25) mmoles/L calcium ions, from 0.4 to 25.0 (preferably about 0.45) mmoles/L magnesium ions, from 96 to 126 (preferably about 118) mmoles/L chloride ions, 2 to 11 mmoles/L (preferably about 10) glucose (preferably D-glucose), from 50 to 150 (preferably about 110) μmoles/L glycerol, from 7 to 15 (preferably about 10) μmoles/L choline, from 5 to 400 (preferably about 300) μmoles/L glutamate (preferably L-glutamate), from 5 to 200 (preferably about 20) μmoles/L aspartate (preferably L-aspartate), from 100 to 2000 (preferably about 400) μmoles/L glutamine (preferably L-glutamine), from 15 to 215 (preferably about 60) μmoles/L pyroglutamate, from 20 to 200 (preferably about 100) μmoles/L arginine (preferably L-arginine), from 1 to 120 (preferably about 40) nmoles/L thiamine pyrophosphate (TPP), from 40 to 70 (preferably about 50) μmoles/L D- or DL or L-carnitine (preferably L-carnitine), and from 5 to 200 (preferably about 28) ml.U./L porcine or human insulin (preferably human insulin). The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein.

    摘要翻译： 其中缓冲液是不是无机磷酸盐缓冲液的生理上可接受的缓冲液的缓冲体液膨胀剂溶液包含浓度比为5:1至1:1的钙离子和镁离子。 非磷酸盐缓冲液可以是生理上可接受的N-取代氨基磺酸缓冲剂，特别是在20℃下水溶液中pKa值为7.1-7.5，最优选N-三（羟甲基）甲基-2-氨基乙磺酸（ TES），3-（N-吗啉代）丙磺酸（MOPS），N，N-双（2-羟乙基）-2-氨基乙磺酸（BES）及其组合。 优选的组分包括100至150（优选约135）mmoles / L钠离子，2.5至6.2（优选约5）mmoles / L钾离子，0.1至2.5（优选约1.25）mmoles / L钙离子，0.4 至25.0（优选约0.45）mmoles / L镁离子，96至126（优选约118）mmoles / L氯离子，2至11mmol / L（优选约10）葡萄糖（优选D-葡萄糖），为50至 5至400（优选约300）μmole/ L谷氨酸（优选L-谷氨酸），5至200（优选约110）μmole/ L甘油，7至15（优选约10）μmole/ L胆碱， 优选约20）μmole/ L天冬氨酸（优选L-天冬氨酸），100至2000（优选约400）μmole/ L谷氨酰胺（优选L-谷氨酰胺），15至215（优选约60）μmole/ L焦谷氨酸， 20至200（优选约100）μmole/ L精氨酸（优选L-精氨酸），1至120（优选约40）nmoles / L硫胺素焦磷酸盐（TPP），来自 40至70（优选约50）μmole/ L D-或DL或L-肉毒碱（优选左旋肉碱）和5至200（优选约28）ml.U./L猪或人胰岛素（优选人胰岛素 ）。 该溶液可用于制备药物和血容量扩张剂，用于治疗血容量不足或用于治疗患有灼伤的受试者的细胞外和间质液的损失，用于治疗受试者的呼吸和/或代谢性酸中毒，用于灌注腹部 用于预防和/或改善再灌注损伤的急性肾衰竭或急性毒性病症的受试者的腹膜透析期间，以及将治疗性，试验和/或协同剂递送至受试者，包括生物制剂，例如 至少一种干细胞，肽或基因组衍生蛋白。